Literature DB >> 1530779

Chronic nonocclusive coronary artery constriction impairs ventricular function, myocardial structure, and cardiac contractile protein enzyme activity in rats.

J M Capasso1, A Malhotra, P Li, X Zhang, J Scheuer, P Anversa.   

Abstract

To determine the effects of chronic nonocclusive coronary constriction on cardiac hemodynamics, structural integrity, and contractile protein enzyme activity, the left coronary artery was narrowed in rats, and measurements of ventricular performance, magnitude, and distribution of tissue damage and myofibrillar Mg2+ and Ca2+ myosin ATPase activities were evaluated 1 month later. In the presence of coronary artery stenosis averaging 58%, three levels of involvement of global cardiac performance were identified, and the rats were divided accordingly. In the first group, only left ventricular end-diastolic pressure (LVEDP) was increased; in the second group, LVEDP and left ventricular +dP/dt and/or -dP/dt were affected; and in the third group, LVEDP, left ventricular +dP/dt and -dP/dt, and right ventricular end-diastolic pressure were impaired. Thus, left ventricular moderate dysfunction, severe dysfunction, and failure occurred with coronary narrowing. On a structural basis, coronary constriction resulted in an ongoing process characterized by acute myocytolytic necrosis and foci of replacement fibrosis in different stages of healing. The number of these lesion profiles in the left ventricular myocardium increased 4.7-, 4.4-, and 8.3-fold in rats with moderate dysfunction, severe dysfunction, and failure, respectively. Biochemically, Mg(2+)-ATPase activity of myofibrils increased biventricularly when moderate dysfunction was present. However, this parameter decreased with the appearance of severe dysfunction, reaching control values in ventricular failure. Ca2+ myosin ATPase activity was reduced in the left ventricle of rats with severe dysfunction and failure, whereas it was elevated in the right ventricle of rats with severe dysfunction. In conclusion, a fixed lesion of the left main coronary artery with a modest reduction in vessel luminal diameter generates a conditioned state of the heart characterized by a continuous loss of myocytes and replacement scarring, which, in combination with alterations in contractile protein enzyme activity, may be responsible for a number of abnormalities in cardiac dynamics ranging from moderate dysfunction to pump failure.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1530779     DOI: 10.1161/01.res.70.1.148

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  5 in total

Review 1.  An update on cardiac troponins as circulating biomarkers in heart failure.

Authors:  Serge Masson; Roberto Latini; Inder S Anand
Journal:  Curr Heart Fail Rep       Date:  2010-03

Review 2.  Role of regulatory proteins (troponin-tropomyosin) in pathologic states.

Authors:  A Malhotra
Journal:  Mol Cell Biochem       Date:  1994-06-15       Impact factor: 3.396

Review 3.  The management of heart failure: a matter of definition?

Authors:  A Harley
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

4.  Guidelines for experimental models of myocardial ischemia and infarction.

Authors:  Merry L Lindsey; Roberto Bolli; John M Canty; Xiao-Jun Du; Nikolaos G Frangogiannis; Stefan Frantz; Robert G Gourdie; Jeffrey W Holmes; Steven P Jones; Robert A Kloner; David J Lefer; Ronglih Liao; Elizabeth Murphy; Peipei Ping; Karin Przyklenk; Fabio A Recchia; Lisa Schwartz Longacre; Crystal M Ripplinger; Jennifer E Van Eyk; Gerd Heusch
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-01-12       Impact factor: 4.733

5.  Elevated High-Sensitivity Troponin I in the Stabilized Phase after an Acute Coronary Syndrome Predicts All-Cause and Cardiovascular Mortality in a Highly Admixed Population: A 7-Year Cohort.

Authors:  Leandro Teixeira de Castro; Itamar de Souza Santos; Alessandra C Goulart; Alexandre da Costa Pereira; Henrique Lane Staniak; Marcio Sommer Bittencourt; Paulo Andrade Lotufo; Isabela Martins Bensenor
Journal:  Arq Bras Cardiol       Date:  2019-01-07       Impact factor: 2.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.